NCT04594746View on ClinicalTrials.gov

Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Atrial Fibrillation
Interventions
DRUG

Amiodarone Hydrochloride

Amiodarone hydrochloride 2000 mg PO to be given as a 10-capsule dose pack and ingested in a single sitting with food

DRUG

Placebo

Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food

Trial Locations (1)

T2N 4Z6

RECRUITING

University of Calgary, Calgary

All Listed Sponsors
lead

University of Calgary

OTHER

NCT04594746 - Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study | Biotech Hunter | Biotech Hunter